Derivation of Induced Pluripotent (Adult) Stem Cell Lines in Minnesota with Superior HLA Compatibility for Manufacturing Clinical Cell Therapy Products

This initiative tackles a key challenge in regenerative medicine: access to clinical-grade starting materials. The project will generate high-quality, regulatory-compliant induced pluripotent (adult) stem cell (iPSC) lines with less risk of the immune system rejecting the cells. These lines will be made available to researchers across Minnesota, enabling the development of versatile, cost-effective cell therapies that can benefit a broad range of patients. By building a local supply of standardized starting materials, the project provides a long-term advantage to Minnesota's research community.